Identifying Thrombophilic Risk by Resistance to Activated Protein C: ProC® Ac R Assay

For clarification of an increased risk for a venous thrombotic event

The identification of resistance to activated Protein C (APC) as well as Protein C and Protein S deficiencies is fundamental when assessing one patient’s thrombotic risk.

Among those patients with functional APC resistance, 90% to 95% have Factor V Leiden promoting increased thrombin generation. The prevalence of Factor V Leiden is estimated as 2 to 15% in the general population and up to 60% in selected cohorts of patients with venous thrombosis. The increase in relative risk of thrombosis associated with Factor V Leiden was estimated to be 5 to 10 fold. A combination with other genetic and/or acquired risk factors for venous thrombosis is considered to result in a synergistic increase in risk of thrombosis for the individuals carrying Factor V Leiden.

ProC® Ac R Assay supports the determination of hereditary thrombophilia as part of the assessment of the patient's individual risk for a thrombotic event.

DADE BEHRING
Every minute of every day™
ProC® Ac R Assay – A Considerable Step Forward for Your Laboratory’s Thrombophilia Panel

ProC® Ac R Assay is intended for screening of APC resistance in human plasma from individuals with Factor V Leiden

Assay characteristics

• High sensitivity and specificity:
  ≥ 98.9 % sensitivity and ≥ 97.2 % specificity were evaluated with Dade Behring coagulation systems (cutoff = 1.8 ratio).

• Excellent precision of results:
  3.7% or lower run-to-run variance with Dade Behring coagulation systems.

• No sample pre-dilution with Factor V deficient plasma.

• Activation of Protein C using snake venom from Vipera Agkistrodon contortrix contortrix and activation of Factor X and Factor V using snake venom from Vipera Russelli.

Easy procedure

• Functional clotting assay.

• Easy integration into your laboratory routine.

Reliable patient results

• Suitable also for patients on stabilized oral anticoagulant or heparin therapy.

• ProC® Ac R ratio for the minimization of effects from potentially interfering substances.

• Good discrimination between positive and negative results comparable to a traditional APTT-based APC resistance assay (using exogenous APC and prediluting the sample with Factor V deficient plasma).

System applications

The following systems have high comparability of ProC® Ac R results

• BCS® System
• Sysmex® CA-7000 System
• Sysmex® CA-1500 System

Dade Behring offers laboratories a broad panel for the assessment of thrombophilia:

• ProC® Global for the investigation of the protein C anticoagulant pathway including Protein C and S deficiencies, and Factor V (Leiden) gene mutation

• ProC® Ac R
• Berichrom® Antithrombin III (A)
• Berichrom® Protein C
• Protein C Clotting
• Protein S Ac

The ProC® Ac R Assay is one way in which Dade Behring demonstrates its commitment to you by developing solutions with the highest level of quality, safety and efficacy, and with service that meets your laboratory’s unique challenges.

For further information please contact your Dade Behring representative.


Sysmex is a registered trademark of Sysmex corporation in the USA, in Germany and other countries. Berichrom is a registered trademark of Dade Behring Marburg GmbH in Germany and other countries. ProC and BCS are registered trademarks of Dade Behring Marburg GmbH in the USA, in Germany and other countries. Information given in this brochure is accurate at the time of printing. Details in the package insert are binding in each individual case. This brochure is for use outside the U.S.

© 02/2005 Dade Behring Holding GmbH, 131555 E 02/05

Dade Behring Marburg GmbH
Dade Behring Holding GmbH
Hoechster Strasse 70
65835 Liederbach, Germany
www.dadebehring.com

Every minute of every day™